Literature DB >> 7964937

Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy.

R B Diasio, Z Lu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7964937     DOI： 10.1200/JCO.1994.12.11.2239

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  20 in total

Review 1.  Gender specific tumour pharmacology--from kinetics to genetics.

Authors:  Robert M Mader
Journal:  Wien Med Wochenschr       Date:  2006-10

2.  Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.

Authors:  Agustin A Garcia; John A Blessing; Kathleen M Darcy; Heinz Josef Lenz; Wu Zhang; Ed Hannigan; David H Moore
Journal:  Gynecol Oncol       Date:  2006-10-17       Impact factor: 5.482

3.  5-Fluorouracil Loaded Chitosan-PVA/Na+MMT Nanocomposite Films for Drug Release and Antimicrobial Activity.

Authors:  A Babul Reddy; B Manjula; T Jayaramudu; E R Sadiku; P Anand Babu; S Periyar Selvam
Journal:  Nanomicro Lett       Date:  2016-03-16

4.  Evaluation of the 5-fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy.

Authors:  Yu Abe; Naoki Sakuyama; Tsuyoshi Sato; Kenji Kishine; Kiichi Nagayasu; Akinori Nakatani; Masayuki Kitajima; Tomoo Watanabe; Kazuhiko Nishimura; Takumi Ochiai; Isao Nagaoka
Journal:  Mol Clin Oncol       Date:  2019-07-03

5.  Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.

Authors:  Elena Magnani; Enrico Farnetti; Davide Nicoli; Bruno Casali; Luisa Savoldi; Chiara Focaccetti; Corrado Boni; Adriana Albini; Maria Banzi
Journal:  Intern Emerg Med       Date:  2013-04-13       Impact factor: 3.397

6.  Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics.

Authors:  Chen-Hsi Hsieh; Yen-Ju Hsieh; Chia-Yuan Liu; Hung-Chi Tai; Yu-Chuen Huang; Pei-Wei Shueng; Le-Jung Wu; Li-Ying Wang; Tung-Hu Tsai; Yu-Jen Chen
Journal:  J Transl Med       Date:  2010-03-25       Impact factor: 5.531

7.  Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.

Authors:  Zhi-xiang Zhuang; Hong Zhu; Ji Wang; Min-gao Zhu; Hui Wang; Wang-yang Pu; Hua-hui Bian; Lei Chen; Hong Zhang
Journal:  Acta Pharmacol Sin       Date:  2013-02-11       Impact factor: 6.150

8.  Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.

Authors:  Kohei Shigeta; Yoshiyuki Ishii; Hirotoshi Hasegawa; Koji Okabayashi; Yuko Kitagawa
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

9.  Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of T3 human colorectal carcinoma.

Authors:  Atsushi Okita; Kazunori Tsukuda; Masakazu Murakami; Tetsuya Ota; Hiroyoshi Doihara; Manabu Suda; Tomoharu Nakano; Kinya Matsuoka; Eiji Suzuki; Minoru Naito; Akio Andou; Nobuyoshi Shimizu
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

10.  Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.

Authors:  Kotaro Miyake; Satoru Imura; Tomoharu Yoshizumi; Tetsuya Ikemoto; Yuji Morine; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.